TMS Co., Ltd.
Notice of Signing a Term Sheet for a Joint Venture Concerning a Clinical Trial Using NOX-A12 for Newly Diagnosed Glioblastoma and Establishment of a Subsidiary
A term sheet was signed with TME Pharma for a joint venture on the GLORIA clinical trial of NOX-A12. A wholly owned subsidiary of TMS Co., Ltd. will be established in Q4 2026 with capital of 50 million yen. Discussions will continue on external financing; whether a license agreement is executed will depend on certain conditions.
Key Figures
- Capital at time of new company establishment: 50 million yen
- Consideration for exclusive negotiation rights: Up to 300,000 euros
- Planned timing for new company establishment: Q4 2026
AI要約
Overview of the Business Partnership
TMS Co., Ltd. has signed a term sheet granting it exclusive negotiation rights to carry out the GLORIA clinical trial for newly diagnosed glioblastoma using NOX-A12 as a joint venture with TME Pharma A.G. The plan is to establish a new company to promote the joint venture; specific terms of any license agreement will be determined through future discussions and based on the status of fundraising.
Establishment of the New Company and Future Schedule
The new company will be 100% funded by TMS Co., Ltd. and is planned to be established in Q4 2026. Capital at the time of establishment will be 50 million yen. The company name, location, and representative at establishment are TBD. After signing the term sheet, whether a license agreement will be executed will be decided taking into account the ability to secure external funding and other factors.
TMS Co., Ltd.
Company overview · Stock price · Financial data · All IR
